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Infectious  diseases  associated  with  antimicrobial  resistance  are considered  to represent  an  important
public  health  problem.  In this  regard,  the  mushroom  Agaricus  blazei  Murrill  contains  several  bioactive
substances  that  promote  signiﬁcant  functional  properties,  among  them,  antimicrobial  activity,  which  has
attracted  the interest  of  the  scientiﬁc  community.  Thus,  the  aim  of  this  study  was  to  determine  whether
evidence  of  the antimicrobial  action  of A.  blazei  has  been  reported  in  the literature.  In  this integrative
review,  manuscripts  held  in  research  databases  available  online  were  examined  with  a view to  answering
the  question  “Does  the  mushroom  A.  blazei  exert antimicrobial  activity  against  Gram-negative  and/or
Gram-positive  bacteria?”  Only  eight  scientiﬁc  articles  that have  addressed  the  antimicrobial  properties
of A.  blazei,  in vitro  and  in  vivo,  were  found,  all characterized  as  pre-clinical,  i.e.,  with  level  VII  evidence.nfection
Most  authors  have  found  that  the A.  blazei  extract  promotes  an  antimicrobial  effect against  peritonitis,  as
well as deadly  oral infections,  especially  those  caused  by  Gram-positive  bacteria.  However,  the  scientiﬁc
data  currently  available  are  not  sufﬁcient  to verify  the  antimicrobial  aspect  of  the  mushroom  A.  blazei
and  thus  further  investigation  is required.
© 2016  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  This  is an  open
he CCaccess  article  under  t
ntroduction
Infectious diseases have become a major public health problem
orldwide. In recent years, antibiotics have been instrumental in
herapy against infections caused by various pathogens (Huttner
t al., 2013). However, there is an increasing resistance to tradi-
ional antibiotics resulting in increased morbidity and mortality,
rolonged hospital stays and increased hospital costs (Davey and
arwick, 2008; Piddock, 2012; Thabit et al., 2015).
Data show that approximately 70% of the bacteria that cause
ospital-acquired infections are resistant to at least one of the drugs
ost commonly used for the treatment (Lambert et al., 2010; Mertz
t al., 2015). In most countries, this rise in antimicrobial resistance
as been found not only in relation to hospital-acquired but also
ommunity-acquired infections (Odonkor and Addo, 2011; Abella
t al., 2015; Fistarol et al., 2015).
The emergence of antimicrobial resistance is facilitated by sev-
ral factors, which are related to bacteria or humans. Antibiotic
esistance is related to particular aspects associated with the
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overall progress of bacteria and these cannot generally be inter-
rupted by humans, for instance, the mutation of bacteria, which is
one of the determining factors of resistance (Licking, 1999; Mah
and O’Toole, 2001; Stokes and Gillings, 2011; Arenz and Wilson,
2016). However, the inadequate application of drug therapy with
antibiotics in humans, with a lack of appropriate criteria or incor-
rect dose, treatment period, active agent etc., can directly inﬂuence
the bacterial resistance to this type of drug (Morgan et al., 2011;
Meyer et al., 2013).
Studies suggest that the mushroom Agaricus blazei Murrill, cul-
tivated in Brazil, contains several bioactive substances responsible
for its medicinal properties (Kasai et al., 2004; Kawamura et al.,
2005; Ellertsen et al., 2006; Cordeiro and Bach, 2006; Smiderle
et al., 2011; Firenzuoli et al., 2007; Machado et al., 2007; Hsu et al.,
2008; Padilla et al., 2009; Jumes et al., 2010; Ishii et al., 2011;
Carneiro et al., 2013; Uyanoglu et al., 2014; Bertéli et al., 2014),
notably glucans which, in addition to promoting an immunomodu-
latory response, can induce an increase in the antimicrobial action
of this fungus (Ohno et al., 2001; Sorimachi et al., 2001; Smyth
et al., 2002; Shimizu et al., 2002; Kaneno et al., 2004; Takimoto
et al., 2004; Kasai et al., 2004; Kawamura et al., 2005; Ellertsen
et al., 2006; Yuminamochi et al., 2007; Smiderle et al., 2011).
Some studies carried out in animals and in vitro have indicated
that pro-inﬂammatory mediators can induce the phagocytosis of
ora Ltda. This is an open access article under the CC BY-NC-ND license (http://
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taphylococcus aureus and Mycobacterium tuberculosis, respectively
Riollet et al., 2000; Kisich et al., 2002). It has been suggested
hat the interpretation of these results could be extrapolated to
. blazei because this mushroom promotes the growth of various
ytokines, particularly pro-inﬂammatories. Thus, the serum lev-
ls resulting from the use of chemokines observed in studies on
. blazei (Sorimachi et al., 2001; Bernardshaw et al., 2005; Ellertsen
t al., 2006; Chan et al., 2007; Johnson et al., 2009) could enhance
he phagocyte power of immune cells and promote the effective-
ess of the response to infection by pathogenic microorganisms.
The signiﬁcant increase in the number of bacteria which are
esistant to a broad spectrum antibiotics has become an urgent
ublic health problem worldwide (WHO, 2011; Kelly et al., 2016;
hudaibergenova, 2015). Considering the rapid spread of multi-
rug resistance, the development of new antimicrobial agents
hich act on newly adapted microorganisms has become a prior-
ty (Laxminarayan et al., 2013; Torjesen, 2013). Some researchers
ave focused on the development of antibiotics from natural prod-
cts that can control infection without encouraging the emergence
f resistant bacterial strains (Gilbert et al., 2010; Sokovic´ et al.,
014). Mushrooms can be considered a source of natural antibi-
tics due to the presence of certain compounds of interest, such as
erpenes, sesquiterpenes, steroids, anthraquinone and derivatives
f benzoic acid, quinolines, oxalic acid, peptides and proteins (Alves
t al., 2012).
Even before the advent of the resistance of micro-organisms
o conventional antibiotics, there was considerable interest in the
tudy of natural products for the therapeutic treatment of infec-
ions promoted by these organisms. In this context, the aim of this
eview paper is to determine whether there is scientiﬁc evidence
vailable to support the antimicrobial action of the mushroom A.
lazei.
ethods
This study is characterized as an integrative review of the
cientiﬁc literature and the aim was to answer the follow-
ng question: “Does the mushroom Agaricus blazei Murrill exert
ntimicrobial activity against Gram-negative and/or Gram-positive
acteria”?
The survey was conducted considering publications indexed
n the following databases: Bireme Library, Cochrane, Homeoin-
ex, Lilacs, Pubmed/Medline, SciElo and ScienceDirect, using
antimicrobial agents’ as controlled descriptors and ‘medicinal
ushrooms’ and ‘Agaricus blazei Murrill’ as uncontrolled descrip-
ors. These descriptors were used in their Portuguese language
ersions in the Lilacs and SciElo databases. Subsequently, a reverse
ookup was held by considering the references cited in the articles
esearched. Scientiﬁc research publications reporting the antimi-
robial action of the mushroom A. blazei Murrill, in Portuguese,
nglish or Spanish, regardless of the year of publication, adopting
ny kind of method, were deﬁned as inclusion criteria.
Data were collected during the period of September–December
014. The documents were found by way of a literature review and
ccessed in collections available online. The selected articles were
ead in full for the purpose of further critical analysis and catego-
ization. Data relating to the journal, author and type of study were
lso evaluated. The studies were then categorized based on the level
f evidence: Level 1: systematic review; Level 2: randomized clin-
cal trial; Level 3: cohort study; Level 4: case–control study; Level
: series of cases; Level 6: expert opinion; Level 7: pre-clinical trial
in vivo/in vitro) as described by Bork (2005). The impact factor of
he journals in which the research included in this study was pub-
ished was identiﬁed using data from the Journal Citation Reports
JCR).rmacognosia 26 (2016) 780–786 781
Results
The total number of published manuscripts addressing the
antimicrobial action of the mushroom A. blazei were eight, from
the years 1994–2014. The impact factors of the journals in which
these publications appeared, determined for the year 2014, ranged
from 0.263 to 3.045 (Table 1). Regarding the category of the stud-
ies, according to the design adopted, it was found that all were
pre-clinical trials; seven performed in vitro and two of the studies
included in the sample group involved research on animals. Only
the study by Bernardshaw et al. (2005) involved both methods cited
above, that is, in vivo and in vitro. It should be noted that all in vivo
studies were predominantly carried out on mice, with the inclusion
of a control group besides the test group.
With regard to the types of A. blazei mushroom extracts
evaluated, it was observed that in two studies a commercially
available aqueous solution was  evaluated, that is, AndoSanTM
(Immunopharma AS, Høvik, Norway) composed of A. blazei mush-
rooms (82%), Hericeum erinaceus (15%) and Grifola frondosa (3%)
(Bernardshaw et al., 2005, 2006). The other authors used extracts
obtained from mushrooms in natura,  speciﬁcally the fruiting bodies
of the Basydiomicetes, using as solvents: hexane, chloroform and
methanol (Osaki et al., 1994); water and ethanol (Zhuqiu and Zhang,
2001); ethanol (Lund et al., 2009); methanol (Stojkovic et al., 2014.);
and water (Sokovic´ et al., 2014). Mazzutti et al. (2012) investigated
the use of the supercritical ﬂuid extraction process to obtain the
A. blazei extract using ethanol as a cosolvent with carbon dioxide
(CO2) and subsequently compared this method with other conven-
tional extraction procedures (extraction by maceration followed by
liquid–liquid partition, hexane and hydrodistillation) using other
solvents, such as hexane, dichloromethane, ethyl acetate, ethanol
and water.
In studies which included animals in the sample group the
use of an orogastric intubation catheter was found to be the
administration route for the A. blazei extracts (Bernardshaw et al.,
2005, 2006). There was  a variety of microorganisms tested in the
studies analyzed, with a predominance of Gram-positive bacte-
ria: Salmonella typhi (Osaki et al., 1994); Staphylococcus aureus,
Bacillus sabtilis,  Escherichia coli (Zhuqiu and Zhang, 2001); Strepto-
coccus pneumoniae serotype 6B pneumococus (Bernardshaw et al.,
2005); coliforms (enterococci, a-hemolytic, hemolytic and non-
hemolytic streptococci) (Bernardshaw et al., 2006); oral mutans
streptococci (Streptococcus mutans UA159 and Streptococcus sobri-
nus 6715) (Lund et al., 2009); Staphylococcus aureus,  Bacillus cereus,
Escherichia coli and Pseudomonas aeruginosa (Mazzutti et al., 2012);
Listeria monocytogenes (Stojkovic et al., 2014); and P. aeruginosa
(Sokovic´ et al., 2014).
Discussion
This research identiﬁed that there is currently a shortage of data
obtained from scientiﬁc studies on the antimicrobial action of the
mushroom A. blazei available. This ﬁnding may  be due to the impor-
tance of other A. blazei properties, such as the immunomodulatory
and antitumor properties, reﬂecting in the scientiﬁc literature and
increasingly prompting researchers to verify these functions when
adopting the various designs for their studies. It is noteworthy
that there was a great diversity of places where the publications
that deal with antimicrobial activity were performed; however, the
English language was  predominant. The values for the ISI impact
factors of the journals in which the publications appeared reveal
that there is quality in the methodology employed by the authors,
promoting a reduction in the bias which could interfere in our
results.
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Table  1
Distribution of manuscripts according to the identiﬁcation, type of study, level of evidence, publication year, journal features and antimicrobial action of Agaricus blazei.
Antimicrobial action Agaricus blazei Type of
study/level of
evidence
Manuscript
authors
Journal Journal Citation
Reports (2014)
Bactericidal action against Salmonella typhi. Preclinical
study (ani-
mals/in vitro)
Osaki et al.,
1994
Yakugaku
Zasshi
0.263
Extracts of A. blazei and aqueous ethanol, did not exercise
antimicrobial activity against the strains tested (S. aureus, B.
sabtilis, E. coli).
Preclinical
study (ani-
mals/in vitro)
Zhuqiu and
Zhang, 2001
Journal Food
Science
2.203
Protective effect against S. pneumoniae 6B infection (24 h when
administered before or together with the inoculation). No
effect on antibiotic pneumococci in vitro.
Preclinical
study (ani-
mals/in vitro)
Bernardshaw
et al., 2005
Scandinavian
Journal of
Immunology
1.739
Reduction in bacteremia and increased survival (↓ lethal
septicemia) in mice with fecal peritonitis.
Preclinical
study (ani-
mals/in vitro)
Bernardshaw
et al., 2006
Shock 3.045
The  ethanol extract (100%) inhibited the growth of
Streptococcus mutans UA159 and Streptococcus sobrinus 6715
using the diffusion method in agar.
In  tests of MIC  and MBC, the three extracts (50%, 75% and
100%) had antimicrobial properties.
Preclinical
study (ani-
mals/in vitro)
Lund et al.,
2009
Pharmaceutical
Biology
1.241
A.  blazei extracts obtained from low pressure techniques (using
various solvents) as well as by supercritical ﬂuid extraction
had a higher antibacterial activity toward Gram positive
bacteria (S. aureus and B. cereus). However, the extracts
tested against Gram-negative bacteria (E. coli, P. aeruginosa)
can be classiﬁed as weak inhibitors.
Preclinical
study (ani-
mals/in vitro)
Mazzutti et al.,
2012
The journal of
supercritical
ﬂuids
2.371
Ethanol extract of A. blazei showed greater antimicrobial
activity against the growth of Listeria monocytogenes when
compared to other mushrooms.
Preclinical
study (ani-
mals/in vitro)
Stojkovic et al.,
2014
Food Funct 2.791
Aqueous extract of A. blazei caused a signiﬁcant reduction in
virulence factors (pyocyanin production, motility) and
bioﬁlm formation of Pseudomonas aeruginosa.
Preclinical
study (ani-
mals/in vitro)
Sokovic´ et al.,
2014
Molecules 2.416
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he  arrows indicate stimulation or inhibition promoted by A. blazei.
The categorization of all studies as preclinical trials, together
ith the small number of articles published in the scientiﬁc litera-
ure, suggests that there is a need for more research to address the
ntimicrobial function of A. blazei,  including the adoption of other
ethods, especially in vivo testing.
The antimicrobial properties of A. blazei have been conﬁrmed
n most research studies using in vitro methods (Osaki et al.,
994; Lund et al., 2009; Mazzutti et al., 2012; Stojkovic et al.,
014; Sokovic´ et al., 2014) and in vivo testing mice, noting
hat in this sample group the mushroom extract exerted action
gainst microorganisms that cause lethal infections caused by
neumococci (Bernardshaw et al., 2005) and fecal peritonitis
Bernardshaw et al., 2006). However, Zhuqiu and Zhang (2001)
ound no antibacterial effects of A. blazei against four differ-
nt types of microorganisms analyzed employing the minimum
nhibitory growth method. In addition, other researchers have
ound that there was no antimicrobial effect of A. blazei using an
n vitro method, although they did observe this property in mice
Bernardshaw et al., 2005). The reason for the negative results
btained in these two studies is probably based on the fact that the
ntimicrobial mechanism of action of bioactive substances present
n the mushroom requires engagement with the immune system,
specially the innate immune system, which cannot be demon-
trated in vitro (Lull et al., 2005).
The results for research which conﬁrmed the antimicrobial
ctivity of extracts of the mushroom A. blazei mostly identiﬁed
reater inhibition for the Gram-positive bacteria (compared with
ram-negative bacteria), such as Salmonella typhi, Streptococcus
neumoniae, Streptococcus mutans, Streptococcus sobrinus, Staphy-
ococcus aureus, B. cereus,  L. monocytogenes and coliforms. Koneman
t al. (1999) suggest that the hypothesis which explains these data
s based on the structural differences presented by Gram-negative
icroorganisms, such as a greater number of ﬂow pumps or thernal Citation Reports.
presence of an outer membrane on the thin peptidoglycan layer
(Schweizer, 2003; Lister et al., 2009; Breidenstein et al., 2011).
The scientiﬁc evidence obtained from all studies analyzed in
this review is closely related to the type of mushroom extract
adopted. Due to the signiﬁcant inﬂuence of certain environmen-
tal and methodological factors, the type and quantity of bioactive
constituents of A. blazei may  vary according to the cultivation
method, climatic and soil conditions, use of raw or dehydrated
mushrooms, use of dry extract, type of solvent extraction, method-
ology employed for the preparation of the solutions and storage
procedure (Dai et al., 2010; Lim et al., 2012; Montoya et al., 2013).
It is important to note that in the two studies where the in vivo
antimicrobial effect of A. blazei was observed (Bernardshaw et al.,
2005, 2006), a commercial aqueous extract was used as the reagent.
Although this product is widely used by the Japanese population,
the description of the chemical composition of this extract is highly
relevant in order to identify the possible compounds responsible
for the antibacterial property and guide future research, and this
was not carried out in the studies in which it was used as a reagent
(Stojkovic et al., 2013; Su et al., 2016).
Alves et al. (2012) conducted a review in order to describe
the antimicrobial properties of extracts obtained from various
mushrooms and highlight some of the active compounds identi-
ﬁed, including compounds of low and high molecular weight. The
researchers found that mushrooms have several antimicrobial sub-
stances represented by low molecular weight compounds which
are mostly secondary metabolites, such as terpenes, sesquiter-
penes and other steroids, anthraquinones, benzoic acid derivatives
and quinoline, as well as primary metabolites such as oxalic acid.
However, peptides and proteins are considered to be the major
antimicrobial compounds of high molecular weight present in
mushrooms. Data in the literature indicate greater antimicro-
bial activity of mushroom extracts against Gram-positive bacteria.
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owever, in this research the mushroom A. blazei was  not men-
ioned.
Currently, it is well established in the literature that the
asiodimycete A. blazei contains various bioactive compounds that
romote a variety of functional properties, acting individually
nd/or synergistically. Thus, it is important to understand which
ctive substances play a role in the antimicrobial action. However,
he scientiﬁc literature does not provide information on which
ioactive compound in A. blazei exercises this function or on the
echanism of action. However, among the hypotheses suggested
y researchers some compounds are notable, such as -glucans
Gonzaga et al., 2009; Yamanaka et al., 2012), antioxidants (Silva
t al., 2009; Mourão et al., 2011; Carvajal et al., 2012; Jia et al.,
013; Hakime-Silva et al., 2013; Wu  et al., 2014), ergosterol (Zou,
006; Gao et al., 2007; Hong and Gu, 2007; Hetland et al., 2008; Shu
nd Lin, 2011), tocopherol (Tsai et al., 2007), agaritine (Endo et al.,
010), phenolic compounds (Soares et al., 2009) and nucleotides
nd nucleosides (Oliveira et al., 2010).
Some researchers have suggested that the antimicrobial action
romoted by A. blazei mushroom extracts can be explained based
n the premise that -glucans stimulate the synthesis and secretion
f cytokines by macrophages (Sorimachi et al., 2001), especially the
ro-inﬂammatory compounds, and activate the complement sys-
em (Shimizu et al., 2002). A. blazei contain a signiﬁcant amount
f -glucans (Hetland et al., 2000; Hetland and Sandven, 2002;
odshall et al., 2003) which, in addition to stimulating the innate
mmune system, exert an antimicrobial effect (Shin et al., 2005;
han et al., 2009).
Recently, Hetland et al. (2013) published a review which
imed to compare the antimicrobial effects of the following types
f polysaccharides: -glucans, pectin and commercial A. blazei
ushroom extract (AndoSanTM). These researchers demonstrated
hat -glucans are present in the structure of yeasts and mush-
ooms and that pectin is present in Plantago major L., these
aving anti-infection properties in various models of mice against
icroorganisms, including bacteria.
The antimicrobial property of -glucans has been veriﬁed
n vitro in macrophages infected with M.  tuberculosis (Hetland and
andven, 2002) and in vivo in mice infected with Mycobacterium
ovis (Hetland et al., 1998). The -glucans promote the stimulation
f the innate immune system through their connection with cer-
ain speciﬁc receptors on immune cells, such as Toll-like receptor 2
TLR2), dectin-1 and CD11b/18. However, mushrooms may  contain
olecular substances other than -glucans, which can similarly
ctivate an innate immune response (Dalonso et al., 2015).
The AndoSanTM extract containing A. blazei,  as well as two other
ypes of mushroom, in its composition, has been analyzed in two
tudies (Bernardshaw et al., 2005, 2006), and its antimicrobial
ction has been conﬁrmed. This is probably exerted by the mush-
oom A. blazei,  since it is present in greater quantity in this extract
hen compared to the other fungi.
The probable mechanism of action associated with the antimi-
robial effects of A. blazei mushroom extract (AndoSanTM) is
ncreased serum levels of pro-inﬂammatory cytokines MIP-2,
hich is equivalent to interleukin-8 (IL-8) in humans, and tumor
ecrosis factor (TNF-)  in mice that received A. blazei mushroom
xtract (Bernardshaw et al., 2005). Alternatively, this protective
ffect could be promoted by A. blazei-mediated innate immunity.
In a study by Bernardshaw et al. (2006) using a model of peri-
onitis in mice it was found that the AndoSanTM extract exerted an
ntimicrobial action and the researchers suggested that the mech-
nism is based on the inhibitory action of TLR-4 receptor-mediated
ell stimulation of NF-kB activation via TLR-2. This mechanism may
xplain the protective effect of the extract in this model of sep-
is induced by Gram-negative microorganisms (Tryggestad et al.,
013).rmacognosia 26 (2016) 780–786 783
According to Hetland et al. (2013), this extract was notable
among the other polysaccharides investigated in this study, that
is, -glucans and pectin, since it was  more effective in terms
of its antimicrobial action, based on previously reported results
(Bernardshaw et al., 2005, 2006).
However, Sokovic´ et al. (2014) hypothesized that the mech-
anism of action associated with the antimicrobial property
promoted by the mushroom A. blazei is not based on the stimulation
of innate immunity, but could be explained by the induction of anti-
quorum (anti-QS). Anti-QS detection compounds have been shown
to disrupt the formation of bioﬁlms and consequently make them
more susceptible to antibiotic bacteria. These compounds are also
able to reduce the virulence factor of the bacteria and promote the
elimination of bacteria in animal models (Ta and Arnason, 2016).
One study investigated the effect of an aqueous extract of A.
blazei on the virulence factors of the quorum system (QS) and
bioﬁlm formation against the bacterium P. aeruginosa.  The results
show that the aqueous extract of A. blazei exhibited antibacterial
action and also anti-quorum activity. The extract had an effect on
all mechanisms tested, promoting a reduction in bioﬁlm formation
and motility and decreasing the synthesis of pyocyanin pigment.
The researchers suggested that this data obtained for the aqueous
extract of A. blazei may  be used for the prevention and/or control
of the growth of P. aeruginosa (Sokovic´ et al., 2014).
One of the substances present in A. blazei is linoleic acid
(Mazzutti et al., 2012), which is considered to be one of the bioactive
components that promote the bactericidal activity of this mush-
room (Fortes and Novaes, 2006). Linoleic acid is considered to be
an essential unsaturated fatty acid, because the human body does
not have the biological capacity to synthesize it (Sanhueza et al.,
2002). This fatty acid has several functions, notably reducing the
serum levels of triglycerides and cholesterol, decreasing the risk
of allergies, cancer and atherosclerosis and antimicrobial activity.
The probable mechanism of action of the antimicrobial activity pro-
moted by the linoleic acid is the ability of this fatty acid to break the
membranes of bacterial cells and cause cell lysis (Lee et al., 2002).
In a recent study the antimicrobial activity of phenolic com-
pounds from different species of mushrooms has been identiﬁed
and quantiﬁed. The researchers found that the phenolic com-
pounds 2,4-dihydroxybenzoic acid and protocatechuic acid have
relatively high antimicrobial activity against most Gram-negative
and Gram-positive bacteria. Furthermore, inhibition provided by
the phenolic compounds was greater than that of the antibiotics
used for the treatment of infection promoted by methicillin-
resistant Staphylococcus aureus (MRSA). MRSA was  inhibited by
2,4-dihydroxybenzoic, vanillic, syringic (MIC = 0 × 5 mg  ml−1) and
p-coumaric (MIC = 1 mg  ml−1) acid. Based on these results the
researchers concluded that the presence of carboxylic acid (COOH),
two hydroxyls (OH), groups in the ortho positions of the benzene
ring and also a methoxyl group (OCH3) in the meta position appears
to be important in relation to the anti-MRSA activity (Alves et al.,
2013).
On the other hand, A. blazei contains a variety of other com-
pounds, such as ergosterol (Takaku et al., 2001), other types of
fatty acids (Huang et al., 2011), polysaccharides (Hu et al., 2015)
and alkaline substances (Ohno et al., 2001) which can also play
an important role in the synergistic antimicrobial action. How-
ever, only one of the studies analyzed in this review reported
the isolation and identiﬁcation of the bactericidal substance
13-hydroxy-cis-9,trans-11-octadecadienoic (13ZE-LOH) extracted
from the fruiting body of A. blazei using chloroform-methanol as a
solvent (Osaki et al., 1994).Another issue to be clariﬁed, based on scientiﬁc theory, is related
to which route for the administration of the A. blazei extracts
employed favors greater absorption of the bioactive substances
and at the same time is the most natural in relation to humans. In
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his regard, studies by Bernardshaw et al. (2005, 2006) have con-
rmed that the oral administration of the A. blazei extract in mice
romoted antimicrobial action. However, some studies in humans
Johnson et al., 2009; Lima et al., 2012) in which other A. blazei
ushroom properties were evaluated did not identify any effect
hen administering the extract of this fungus orally.
Based on the data presented it appears that there is still not suf-
cient scientiﬁc evidence to support the antimicrobial action of A.
lazei mushroom. The favorable results obtained in the majority of
n vitro and in vivo studies regarding this property have attracted the
nterest of the scientiﬁc community encouraging further research.
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